The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

HealthDay News — Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published online Oct. 23 in JAMA Otolaryngology-Head & Neck Surgery.

A Thai woman condemned a private hospital in the central province of Samut Sakhon after treatment for nasal polyps left her boyfriend blind.

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

The national consumer disputes redressal commission (NCDRC) has upheld the Rajasthan state consumer commission’s finding of ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...